JP Morgan Maintains Overweight on Conmed, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus has maintained an Overweight rating on Conmed (NYSE:CNMD) but has lowered the price target from $115 to $75.
April 25, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan maintains an Overweight rating on Conmed but lowers the price target from $115 to $75.
The reduction in price target by JP Morgan, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors, potentially impacting CNMD's stock price negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100